Controlled release formulation of divalproex sodium
US6419953B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 18, 1998 |
| Grant date | Jul 16, 2002 |
| Priority date | — |
| Expiry date | Dec 18, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to a hydrophilic matrix tablet suitable for the once-a-day administration of valproate compounds such as divalproex sodium. The tablet comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weight percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent of silicon dioxide; all weight percentages based upon the total weight of the tablet dosage form. Other aspects of the invention relate to the use of this formulation in the treatment of epilepsy and to methods for manufacturing this dosage form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.